Abstract:Objective To investigate the role of circulating Th17 cells and IL-17 in myasthenia gravis(MG).Methods Forty MG patients and 10 healthy controls(HC) were recruited.The proportion of Th17 cells in peripheral blood mononuclear cells(PBMCs) was detected via flow cytometry.The transcription factor RORγt mRNA expression in PBMCs was detected with Reverse Transcription-Polymerase Chain Reaction (RT-PCR).The concentration of cytokine IL-17 in sera was measured by ELISA.The anti-human AChR antibody in the serum was assayed using the radioimmunoprecipitation method.CD19+ B cells and CD4+ T cells were isolated from PBMCs of MG patients and healthy controls at the presence of SEB.The anti-AChR antibody secretion in T/B cells co-culture supernatant was detected by radioimmunoprecipitation.The effects of inhibiting IL-17 or IL-21 were examined by adding anti-IL-17 or IL-21 neutralizing antibody in the co-culture system.A quantitative MG scoring system (QMG score) was used to objectively evaluate the disease severity.Then, we analyzed the correlation between Th17 cells proportion, serum IL-17 level, RORγt mRNA and QMG scores.Results The percentage of Th17 cells increased significantly in PBMCs of MG patients compared with HC(P<0.0001), and Th17 cells counts was positively correlated with disease severity(r=0.4394, P=0.0046).Th17 cell-associated transcription factors RORγt mRNA and cytokines IL-17 expression elevated in MG patients(P<0.001).The titers of anti-AChR antibody(AChR-Ab)increased significantly in MG patients compared with HC(P<0.001), and the titer of AChR-Ab was positively correlated with disease severity.High level of anti-AChR antibody was detected in the co-culture of patients T and B cells.Blocking IL-17 or IL-21 alone by neutralizing antibodies led to a moderate decrease of anti-AChR antibody titer, while simultaneous blockage of IL-17 and IL-21 resulted in dramatically decrease of anti-AChR antibody titer.Conclusions In creased Th17 cell was involved in the pathological process of MG, and exacerbated its severity probably via enhanced AChR-Ab production.

Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR

Non-neuronal cholinergic activity is potentiated in myasthenia gravis

The Limitation of IL-10-exposed Dendritic Cells in the Treatment of Experimental Autoimmune Myasthenia Gravis and Myasthenia Gravis

Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.

Cytokines and the Pathogenesis of Myasthenia Gravis

The circulating Th17 cells enhance AChR antibody production in myasthenia gravis patients

Mucosal Tolerance to Experimental Autoimmune Myasthenia Gravis is Associated with Down‐regulation of AChR‐specific IFN‐γ‐expressing Th1‐like Cells and Up‐regulation of TGF‐β Mrna in Mononuclear Cells

IL-10 Suppresses Experimental Autoimmune Neuritis and Down-regulates TH1-Type Immune Responses

The Effect of CD3-specific Monoclonal Antibody on Treating Experimental Autoimmune Myasthenia Gravis.

Both CD4+ and CD8+ T Cells Are Essential to Induce Experimental Autoimmune Myasthenia Gravis.

Anti-TNF-alpha antibodies suppress the development of experimental autoimmune myasthenia gravis.

IL-6 receptor antibody treatment improves muscle weakness in experimental autoimmune myasthenia gravis mouse model

Effects of recombinant IL-2 and T-cell subsets on peripheral B cells in patients with myasthenia gravis

Suppression of Experimental Autoimmune Myasthenia Gravis by Nasal Administration of Acetylcholine Receptor

Cellular mRNA expression of interferon-gamma (IFN-gamma), IL-4 and IL-10 relates to resistance to experimental autoimmune myasthenia gravis (EAMG) in young Lewis rats.

Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cells.

Mice with IFN-gamma Receptor Deficiency Are Less Susceptible to Experimental Autoimmune Myasthenia Gravis.

[Mechanism of Th1/Th2 Cytokines in HLA-DQ8 Transgenic Mice Model of Ocular Experimental Autoimmune Myasthenia Gravis].

Dendritic Cells Exposed in Vitro to TGF-beta1 Ameliorate Experimental Autoimmune Myasthenia Gravis

Effects of Compound Yiqi Jiedu Decoction on CXCL13 and IL-21 in Rats with Experimental Autoimmune Myasthenia Gravis

Inhibitory IgG Receptor FcγRIIB Fails to Inhibit Experimental Autoimmune Myasthenia Gravis Pathogenesis